$NUMD
Nu-Med Plus Inc

2024 Q1 Form 10-K Financial Statement

#000154812324000025 Filed on March 26, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $20.58K $55.34K $120.5K
YoY Change -23.69% 766.04% -33.0%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $20.58K $55.34K $120.5K
YoY Change -23.7% 766.04% -33.84%
Operating Profit -$20.58K -$120.5K
YoY Change -23.7% -33.84%
Interest Expense $1.247K -$1.260K -$5.000K
YoY Change 1.14% 26.0% -600.0%
% of Operating Profit
Other Income/Expense, Net -$1.247K $500.00
YoY Change -349.4% 0.0%
Pretax Income -$21.83K -$56.60K -$125.5K
YoY Change -22.59% -232.83% -3.57%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$21.83K -$56.60K -$125.5K
YoY Change -22.61% -232.83% -3.57%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 83.55M shares 81.35M shares 81.67M shares
Diluted Shares Outstanding 83.55M shares 81.67M shares

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.360K $6.810K $6.810K
YoY Change -88.01% -90.7% -90.7%
Cash & Equivalents $6.356K $6.806K
Short-Term Investments
Other Short-Term Assets $2.660K $6.650K $6.650K
YoY Change 4.72% 4.72% 4.72%
Inventory
Prepaid Expenses $2.660K $6.650K
Receivables
Other Receivables
Total Short-Term Assets $9.016K $13.46K $13.46K
YoY Change -84.74% -83.08% -83.08%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $9.016K $13.46K $13.46K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $9.016K $13.46K $13.46K
YoY Change -84.74% -83.08% -83.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $16.46K $8.089K $54.21K
YoY Change 20.24% 12.47% 30.41%
Accrued Expenses $14.55K $6.000K $6.000K
YoY Change 551.46% 500.0% 500.0%
Deferred Revenue
YoY Change
Short-Term Debt $100.0K $100.0K $100.0K
YoY Change 0.0% 0.0% 0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $177.6K $160.2K $160.2K
YoY Change 18.16% 12.37% 12.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $177.6K $160.2K $160.2K
Total Long-Term Liabilities $0.00
Total Liabilities $177.6K $160.2K $160.2K
YoY Change 18.16% 12.37% 12.37%
SHAREHOLDERS EQUITY
Retained Earnings -$9.847M -$9.825M
YoY Change 1.22% 1.29%
Common Stock $83.55K $83.55K
YoY Change 2.7% 2.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$168.6K -$146.8K -$146.8K
YoY Change
Total Liabilities & Shareholders Equity $9.016K $13.46K $13.46K
YoY Change -84.74% -83.08% -83.08%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$21.83K -$56.60K -$125.5K
YoY Change -22.61% -232.83% -3.57%
Depreciation, Depletion And Amortization $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities -$450.00 -$4.280K -$66.39K
YoY Change -97.77% -82.48% 72.53%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -$450.00 -4.280K -$66.39K
Cash From Investing Activities
Cash From Financing Activities 0.000
Net Change In Cash -$450.00 -4.280K -$66.39K
YoY Change -97.77% -105.66% -207.91%
FREE CASH FLOW
Cash From Operating Activities -$450.00 -$4.280K -$66.39K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
000-54808
CY2023 dei Entity Registrant Name
EntityRegistrantName
NU-MED PLUS, INC
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
UT
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-3672530
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
640 Belle Terre Rd Building 2 E
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Port Jefferson
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
11777
CY2023 dei City Area Code
CityAreaCode
(631)
CY2023 dei Local Phone Number
LocalPhoneNumber
403-4337
CY2023 dei Security12b Title
Security12bTitle
None
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
872427 usd
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
83548469 shares
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 dei Auditor Name
AuditorName
Fruci & Associates II, PLLC
CY2023 dei Auditor Location
AuditorLocation
Spokane, Washington
CY2023Q4 us-gaap Cash
Cash
6806 usd
CY2022Q4 us-gaap Cash
Cash
73195 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6650 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6350 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
13456 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
79545 usd
CY2023Q4 us-gaap Assets
Assets
13456 usd
CY2022Q4 us-gaap Assets
Assets
79545 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8089 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7192 usd
CY2023Q4 numd Accounts Payable Related Party Current
AccountsPayableRelatedPartyCurrent
46118 usd
CY2022Q4 numd Accounts Payable Related Party Current
AccountsPayableRelatedPartyCurrent
34378 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
100000 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
100000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
160207 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
142570 usd
CY2023Q4 us-gaap Liabilities
Liabilities
160207 usd
CY2022Q4 us-gaap Liabilities
Liabilities
142570 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83548469 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83548469 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
81348469 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
81348469 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
83549 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-12553 usd
CY2023 us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
11740 usd
CY2022 us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
8378 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
81349 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
9594687 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
9555087 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9824987 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9699461 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-146751 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-63025 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13456 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
79545 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27557 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26569 usd
CY2023 us-gaap Salaries And Wages
SalariesAndWages
41800 usd
CY2022 us-gaap Salaries And Wages
SalariesAndWages
24095 usd
CY2023 numd Operating Rent Expense
OperatingRentExpense
12900 usd
CY2022 numd Operating Rent Expense
OperatingRentExpense
12971 usd
CY2023 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
38269 usd
CY2022 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
116265 usd
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2267 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
120526 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
182167 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-120526 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-182167 usd
CY2022 numd Gain On Forgiveness Of Debt
GainOnForgivenessOfDebt
50000 usd
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
3000 usd
CY2023 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-5000 usd
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1000 usd
CY2023 us-gaap Other Income
OtherIncome
-5000 usd
CY2022 us-gaap Other Income
OtherIncome
52000 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-125526 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-130167 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-125526 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-130167 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
81673948 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79951209 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-132358 usd
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
35000 usd
CY2022 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
164500 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-130167 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-63025 usd
CY2023 numd Stock Issued During Period Value Common Stock Issued For Compensation
StockIssuedDuringPeriodValueCommonStockIssuedForCompensation
41800 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-125526 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-146751 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-125526 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-130167 usd
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2267 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
41800 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
35000 usd
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
8222 usd
CY2022 numd Gain On Forgiveness Of Debt
GainOnForgivenessOfDebt
50000 usd
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
300 usd
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
6350 usd
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-8222 usd
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
897 usd
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5000 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
114945 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-66389 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38480 usd
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
100000 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
100000 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-66389 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
61520 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73195 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11675 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6806 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73195 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">b. Estimates</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.</p>
CY2023 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
500 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-125526 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-130167 usd
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
81673948 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79951209 shares
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81673948 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79951209 shares
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2023 us-gaap Weighted Average Numer Diluted Limited Partnership Units Outstanding Adjustment
WeightedAverageNumerDilutedLimitedPartnershipUnitsOutstandingAdjustment
0 shares
CY2022 us-gaap Weighted Average Numer Diluted Limited Partnership Units Outstanding Adjustment
WeightedAverageNumerDilutedLimitedPartnershipUnitsOutstandingAdjustment
0 shares
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">g. Concentrations and Credit Risk</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has relied on a small group of investors to fund its operations. If this group becomes unable or unwilling to provide additional funding,the Company may be unable to remain in business or to execute on its business plan.</p>
CY2023 numd Planned Expenditures
PlannedExpenditures
1250000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
90368 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
90368 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
90368 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
90368 usd
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2267 usd
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
41800 usd
CY2023Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.019
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
35000 usd
CY2022Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.0175
CY2023 numd Monthly Office Rent Expenses
MonthlyOfficeRentExpenses
1000 usd
CY2023 us-gaap Other Expenses
OtherExpenses
500 usd
CY2022Q3 us-gaap Convertible Debt
ConvertibleDebt
100000 usd
CY2023 us-gaap Debt Conversion Converted Instrument Rate
DebtConversionConvertedInstrumentRate
0.20 pure
CY2023 numd Income Tax Reconciliation Nondeductible Expense Book Income Loss
IncomeTaxReconciliationNondeductibleExpenseBookIncomeLoss
32637 usd
CY2022 numd Income Tax Reconciliation Nondeductible Expense Book Income Loss
IncomeTaxReconciliationNondeductibleExpenseBookIncomeLoss
33843 usd
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Depreciation
IncomeTaxReconciliationNondeductibleExpenseDepreciation
-589 usd
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
32637 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
33254 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2198579 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2073033 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
2267 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2198579 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2070766 usd
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
14606913 usd
CY2023 dei Auditor Firm
AuditorFirmId
5525
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
usd
CY2023 us-gaap Revenues
Revenues
usd
CY2022 us-gaap Revenues
Revenues
usd
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
usd
CY2023 numd Gain On Forgiveness Of Debt
GainOnForgivenessOfDebt
usd
CY2023 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79951209 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81673948 shares
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
usd
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
usd
CY2023 numd Gain On Forgiveness Of Debt
GainOnForgivenessOfDebt
usd
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
usd
CY2023 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
usd
CY2023 us-gaap Interest Paid
InterestPaid
usd
CY2023 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2023Q4 us-gaap Property Plant And Equipment Other Net
PropertyPlantAndEquipmentOtherNet
usd
CY2022Q4 us-gaap Property Plant And Equipment Other Net
PropertyPlantAndEquipmentOtherNet
usd
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
usd
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Depreciation
IncomeTaxReconciliationNondeductibleExpenseDepreciation
usd
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
usd
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
usd
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Meals And Entertainment
IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
usd
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Meals And Entertainment
IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
usd
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Amortization
IncomeTaxReconciliationNondeductibleExpenseAmortization
usd
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Amortization
IncomeTaxReconciliationNondeductibleExpenseAmortization
usd
CY2023 numd Income Tax Reconciliation Nondeductible Expense Gain Loss On Derivative
IncomeTaxReconciliationNondeductibleExpenseGainLossOnDerivative
usd
CY2022 numd Income Tax Reconciliation Nondeductible Expense Gain Loss On Derivative
IncomeTaxReconciliationNondeductibleExpenseGainLossOnDerivative
usd
CY2023Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
usd
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001543637

Files In Submission

Name View Source Status
0001548123-24-000025-index-headers.html Edgar Link pending
0001548123-24-000025-index.html Edgar Link pending
0001548123-24-000025.txt Edgar Link pending
0001548123-24-000025-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.gif Edgar Link pending
MetaLinks.json Edgar Link pending
numd-20231231.htm Edgar Link pending
numd-20231231.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
numd-20231231_cal.xml Edgar Link unprocessable
numd-20231231_def.xml Edgar Link unprocessable
numd-20231231_htm.xml Edgar Link completed
numd-20231231_lab.xml Edgar Link unprocessable
numd-20231231_pre.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable